Novartis Shares Plunge After Late-Stage Trial Fails for Neuromuscular Drug Candidate

Novartis stock dropped more than 10% after announcing that its experimental treatment for a neuromuscular disease missed its primary goal in a late-stage clinical trial. This marks the third recent setback for the pharmaceutical company’s development pipeline.

8 Sept, 05:48 — 8 Sept, 12:01

Post Share

Why this matters

Novartis’s heavy reliance on external acquisitions like Avidity has become a high-stakes strategy in an industry where internal R&D success rates are declining. Repeated late-stage failures threaten shareholder confidence, potentially impacting dividend sustainability and limiting capital for future innovation. Investors are closely watching whether this signals a temporary stumble or a fundamental shift in the company’s development capabilities.

Key entitiesNovartis del-desiran Avidity Biosciences Dyne Therapeutics Sarepta Therapeutics

The Story

What 11 sources agree on, dispute, and miss

What sources agree on

Novartis shares fell between 10% and 13% following the trial results
The failed candidate was del-desiran, a neuromuscular treatment
This represents the company’s third clinical trial setback in one week
Novartis previously acquired Avidity Biosciences for roughly $12 billion

Key claims4 agreed · 1 unverified

✓

Novartis shares declined between 10% and 13% on the day of the announcement

agreed·bloombergseeking-alphacnbc20-minuten

✓

The failed medication was named del-desiran

agreed·bloombergcnbcReuterswsj

✓

This trial failure marks Novartis's third clinical setback within a seven-day period

agreed·bloombergcnbcFT

The stock decline negatively impacted peer biotechnology companies including Dyne Therapeutics and Sarepta Therapeutics

unverified·seeking-alpha

✓

Novartis completed its acquisition of Avidity Biosciences for approximately $12 billion

agreed·bloomberg

Where they diverge

Strategic vs. operational framing of the failure

bloombergwsj

Frames the setback through the lens of capital allocation and the strategic risks of the $12B Avidity acquisition

FTcnbc

Emphasizes chronic pipeline weakness and repeated clinical misfires as signs of deeper R&D dysfunction

Market contagion emphasis

seeking-alpha

Highlights immediate spillover effects, noting how the drop dragged down peer biotechs like Dyne and Sarepta

Reutersmorningstar

Focuses exclusively on Novartis’s internal valuation and dividend implications without discussing sector-wide contagion

Coverage gaps

Specific regulatory next steps or potential FDA advisory committee discussions

ReportedFT

MissingbloombergcnbcReuters+1

Detailed breakdown of the $12B Avidity deal terms and integration status

Reportedbloomberg

MissingFTcnbcReuters+1

The Story

Analyzing sources…

Source Diversity

Excellent (76/100)

11 sources33/33

Spectrum spread— 3/5 buckets covered17/33

Far L

Left3

Left (3)

globe-and-mailcnbcindex-hr

Center6

Center (6)

bloombergFT20-minuteninvesting-comReutersmorningstar

Right2

Right (2)

seeking-alphawsj

Far R

Geographic diversity— 6 regions26/34

US6Canada1UK1Switzerland1Croatia1Intl1

Political spectrum

LeftCenterRight

index-hr

cnbc

bloomberg

Sources

Showing 7 of 11 sources

ReutersVery High7h ago

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis faces fresh blow to pipeline with del-desiran drug setback reuters.com

Read full article →

bloombergHigh3h ago

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)

Read full article →

cnbcMostly Factual5h ago

Pharma major plummets over 10% after third trial disappointment in a week

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Read full article →

globe-and-mailHigh1h ago

Novartis shares fall after second major trial setback in days

Failed clinical trial for recently acquired drug del-desiran piles pressure on Swiss drugmaker’s pipeline and CEO

By Bhanvi Satija and Dave Graham and Marleen Kaesebier

Read full article →

morningstar7h ago

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial Morningstar

Read full article →

seeking-alphaMixed4h ago

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Read full article →

investing-com5h ago

Why is Novartis stock tumbling today?

By Investing.com

Read full article →

Coverage Timeline

First report: morningstar · 8 Sept, 05:48|Full coverage: 11 · 6h|Window: 6h

Left-leaningCenterRight-leaning

morningstar8 Sept, 05:48First to report

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

wsj8 Sept, 05:54

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - WSJ

Reuters8 Sept, 06:05

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

1h later

index-hr8 Sept, 07:28

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

1h later

bloomberg8 Sept, 10:13

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

2h later

globe-and-mail8 Sept, 12:01Latest update

Novartis shares fall after second major trial setback in days

Story evolution

The narrative quickly evolved from a straightforward clinical update to a broader assessment of Novartis’s acquisition-driven growth model and near-term financial stability.

Initial DisclosureSept 8, 05:48–06:05 UTC

Reuters and WSJ publish breaking reports confirming the del-desiran trial missed its primary endpoint

Market ReactionSept 8, 07:28–08:41 UTC

Financial networks and exchanges report a sharp 10–13% share price drop as trading opens

Strategic & Sector AnalysisSept 8, 08:56–10:13 UTC

Outlets contextualize the miss against the $12B Avidity acquisition and note spillover effects on peer biotechs

Novartis Shares Plunge After Late-Stage Trial Fails for Neuromuscular Drug Candidate

Why this matters

The Story

What sources agree on

Key claims4 agreed · 1 unverified

Where they diverge

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Pharma major plummets over 10% after third trial disappointment in a week

Novartis shares fall after second major trial setback in days

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Why is Novartis stock tumbling today?

Coverage Timeline

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - WSJ

Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com

Brašno čuvate u originalnoj vrećici? Zašto to i nije najbolja ideja

Pharma major plummets over 10% after third trial disappointment in a week

Why is Novartis stock tumbling today?

Studie verfehlt Hauptziel: Mega-Absturz von Novartis-Aktie

Novartis shares slide after drug for muscular disease fails trial

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback

Novartis shares fall after second major trial setback in days

Story evolution

Related Stories

Jaguar Land Rover to Cut 4,000 Jobs in Cost-Reduction Drive

Greece Unveils Plan to Cut Electricity Prices by 30% by 2029

EU Court Rules IKEA Can Block Belgian Far-Right Party’s Use of Its Name

Volkswagen Sells German Plant to Defense Contractor for Missile Defense Production

Why this matters

Story evolution

The Story

What sources agree on

Key claims4 agreed · 1 unverified

Where they diverge

Coverage gaps

Political spectrum

Coverage matrix(11 sources)